New Inhaled Antibiotic To Treat Respiratory Infections

https://www.europeanpharmaceuticalreview.com/news/67983/polyphor-antibiotic-murepavadin/

Polyphor launches the development of an inhaled antibiotic murepavadin

Polyphor Ltd has announced the development of an inhaled dosage form of its break­through antibiotic Murepavadin. Continue reading New Inhaled Antibiotic To Treat Respiratory Infections

Microbiologists uncover clues to clustering of lethal bacteria in CF patients’ lungs

ahttps://www.eurekalert.org/pub_releases/2017-10/iuui-imu100517.php

IUPUI microbiologists uncover clues to clustering of lethal bacteria in CF patients’ lungs

Individuals with cystic fibrosis, or CF, have a high risk of chronic pneumonia because the thick, sticky mucus that builds up in Continue reading Microbiologists uncover clues to clustering of lethal bacteria in CF patients’ lungs

New Nitric Oxide Treatment Eradicates Emerging ‘Superbugs’

http://markets.businessinsider.com/news/stocks/New-Nitric-Oxide-Treatment-Eradicates-Emerging-Superbugs-1002996746

Novoclem Therapeutics, a biotech company focused on advancing nitric oxide therapies for the treatment of respiratory diseases, today announced that data from an in vitro study with Continue reading New Nitric Oxide Treatment Eradicates Emerging ‘Superbugs’

Phase III study starts AVAIL study

Savara Announces Start of Pivotal Phase III AVAIL Study of AeroVanc

http://markets.businessinsider.com/news/stocks/Savara-Announces-Start-of-Pivotal-Phase-III-AVAIL-Study-of-AeroVanc-1002569033

Savara, Inc.(NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development Continue reading Phase III study starts AVAIL study

Scientists find new way to attack antibiotic-resistant lung infections

http://www.cbc.ca/news/health/cystic-fibrosis-biofilms-1.4229907

Canadian scientists have discovered a possible way to break through the defences of some antibiotic-resistant respiratory infections.

It’s hoped that the findings could someday benefit people with cystic fibrosis and other chronic lung diseases who are at greater risk of infections. Continue reading Scientists find new way to attack antibiotic-resistant lung infections

New Drug Application Submitted for Treatment of P. aeruginosa

https://bronchiectasisnewstoday.com/2017/07/28/non-cystic-fibrosis-bronchiectasis-candidate-therpay-nda-submitted-for-linhaliq-for-p-aeruginosa-infection/

New Drug Application Submitted for Linhaliq as Treatment of Pseudomonas Aeruginosa Infection in NCFBE Patients

The pharmaceutical company Aradigm has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Linhaliq Continue reading New Drug Application Submitted for Treatment of P. aeruginosa

French Biotech Receives an Award to Develop a Novel Cystic Fibrosis Antibiotic

https://labiotech.eu/antabio-carb-x-cystic-fibrosis/

CARB-X has awarded $8.9M (€7.6M) to Antabio for the development of a new antibiotic against resistant Pseudomonas infections in cystic fibrosis patients.

Antabio is a French company developing new antibiotics to fight the rapidly Continue reading French Biotech Receives an Award to Develop a Novel Cystic Fibrosis Antibiotic

My Wish List for the New Year By Gunnar Esiason

I’m not naïve enough to think that I’m going to wake up tomorrow and find that my life is moving forward with cystic fibrosis in the rearview mirror.

We’re still a little bit away from that moment, but that doesn’t mean I don’t have high expectations for treatment development. Continue reading My Wish List for the New Year By Gunnar Esiason

Pitt study links cystic fibrosis lung inflammation to opportunistic bacteria

http://www.bizjournals.com/

An investigation led by the University of Pittsburgh School of Medicine has found a link between a new class of bacterial enzymes and the chronic lung inflammation that plagues patients with cystic fibrosis, a terminal lung Continue reading Pitt study links cystic fibrosis lung inflammation to opportunistic bacteria